University of Tennessee Health Science Center, Tennessee, Memphis, TN 38105, USA.
Epilepsy Curr. 2010 Jan;10(1):1-6. doi: 10.1111/j.1535-7511.2009.01336.x.
The last 20 years have witnessed a tremendous explosion in the number of antiepileptic drugs (AEDs) as well as the introduction of AEDS developed for specific epilepsy syndromes. The study of the efficacy and side effect profile of AEDs for unique epilepsy syndromes has allowed neurologists to utilize evidence-based medicine when treating patients. In late 2008, the Food and Drug Administration approved rufinamide for adjunctive use in the treatment of seizures associated with Lennox-Gastaut syndrome. This unique chemical compound is also the first new AED to reach the market in the United States having a pediatric indication prior to approval for adults. Rufinamide appears to have a broad spectrum of efficacy, is well tolerated, and may be rapidly initiated--properties that will likely extend its use outside of Lennox-Gastaut syndrome.
过去 20 年里，抗癫痫药物（AEDs）的数量呈爆炸式增长，同时也出现了针对特定癫痫综合征的 AEDs。对用于治疗特殊癫痫综合征的 AEDs 的疗效和副作用的研究使神经科医生能够在治疗患者时使用循证医学。2008 年末，美国食品和药物管理局批准鲁非尼胺作为辅助治疗 Lennox-Gastaut 综合征相关癫痫发作的药物。这种独特的化合物也是第一个在美国上市的新型 AED，在获得成人批准之前，它已经具有儿科适应证。鲁非尼胺似乎具有广谱疗效，耐受性良好，并且可以快速启动——这些特性可能会使其在 Lennox-Gastaut 综合征之外得到更广泛的应用。
